

10634177

FILE 'HOME' ENTERED AT 18:46:37 ON 16 NOV 2004)

FILE 'REGISTRY' ENTERED AT 18:46:53 ON 16 NOV 2004

L1 STRUCTURE UPLOADED
L2 0 S L1

FILE 'BEILSTEIN' ENTERED AT 18:47:48 ON 16 NOV 2004

L3 0 S L1
L4 0 S L1 SSS FULL

FILE 'REGISTRY' ENTERED AT 19:02:37 ON 16 NOV 2004

L5 3 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 19:03:16 ON 16 NOV 2004


=> s 15

L6 1 L5

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d bib abs hitstr

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:143150 CAPLUS

DN 140:175193

TI Heterobicyclic metalloproteinase inhibitors, pharmaceutical compositions,
and therapeutic use

IN Wilson, Michael William

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 96 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014908	A1	20040219	WO 2003-IB3478	20030804
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004039012	A1	20040226	US 2003-634177	20030805
c PRAI	US 2002-403098P	P	20020813		
OS	MARPAT 140:175193				
GI					




AB The invention discloses fused bicyclic metalloproteinase inhibitors I [A = C2-6 alkynyl, bond, etc.; X, Y = O, S, etc. (with proviso); dashed lines = optional double bonds; B = substituted pyridinyl; R1 = C1-6 alkyl, C2-6 alkenyl, etc.], as well as pharmaceutical compns. and methods of treating arthritis, inflammation, cancer, and other disorders.

IT 658037-50-4 658037-51-5 658037-52-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterobicyclic metalloproteinase inhibitors, pharmaceutical compns., and therapeutic use)


RN 658037-50-4 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)




RN 658037-51-5 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 658037-52-6 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyridine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>